Phage therapy for Clostridium difficile infection: An alternative to antibiotics?

William Sangster, John P. Hegarty, David Stewart

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

As a consequence of their widespread use, a critical limitation in current antibiotic therapy is bacterial resistance. In the case of Clostridium difficile infection (CDI), current antibiotic regimens may not necessarily suffer due to drug resistance, though they have become increasingly ineffective due to the dysbiosis they induce, resulting in notoriously high recurrence rates. As a result, interest in alternative treatment modalities has recently surfaced. Amongst these emerging treatments, newer investigations are being invested in the older concept of bacteriophage therapy. This approach, first identified in the early 19th century, offers a more microbe-specific treatment option that can, theoretically, pointedly target C. difficile while sparing the other bacterial organisms of the human gut. The aim of this article is to explain the intellection behind bacteriophage therapy for the treatment of bacterial infections in humans, to review the historical research on bacteriophage therapy, and to introduce the reader to recent investigations into bacteriophage therapy for the treatment of CDI.

Original languageEnglish (US)
Pages (from-to)167-170
Number of pages4
JournalSeminars in Colon and Rectal Surgery
Volume25
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Clostridium Infections
Clostridium difficile
Anti-Bacterial Agents
Therapeutics
Dysbiosis
Bacterial Infections
Drug Resistance
Phage Therapy
Recurrence
Research

All Science Journal Classification (ASJC) codes

  • Surgery
  • Gastroenterology

Cite this

Sangster, William ; Hegarty, John P. ; Stewart, David. / Phage therapy for Clostridium difficile infection : An alternative to antibiotics?. In: Seminars in Colon and Rectal Surgery. 2014 ; Vol. 25, No. 3. pp. 167-170.
@article{fa3d8c1547764bf589c551c660b61a2b,
title = "Phage therapy for Clostridium difficile infection: An alternative to antibiotics?",
abstract = "As a consequence of their widespread use, a critical limitation in current antibiotic therapy is bacterial resistance. In the case of Clostridium difficile infection (CDI), current antibiotic regimens may not necessarily suffer due to drug resistance, though they have become increasingly ineffective due to the dysbiosis they induce, resulting in notoriously high recurrence rates. As a result, interest in alternative treatment modalities has recently surfaced. Amongst these emerging treatments, newer investigations are being invested in the older concept of bacteriophage therapy. This approach, first identified in the early 19th century, offers a more microbe-specific treatment option that can, theoretically, pointedly target C. difficile while sparing the other bacterial organisms of the human gut. The aim of this article is to explain the intellection behind bacteriophage therapy for the treatment of bacterial infections in humans, to review the historical research on bacteriophage therapy, and to introduce the reader to recent investigations into bacteriophage therapy for the treatment of CDI.",
author = "William Sangster and Hegarty, {John P.} and David Stewart",
year = "2014",
month = "1",
day = "1",
doi = "10.1053/j.scrs.2014.05.014",
language = "English (US)",
volume = "25",
pages = "167--170",
journal = "Seminars in Colon and Rectal Surgery",
issn = "1043-1489",
publisher = "W.B. Saunders Ltd",
number = "3",

}

Phage therapy for Clostridium difficile infection : An alternative to antibiotics? / Sangster, William; Hegarty, John P.; Stewart, David.

In: Seminars in Colon and Rectal Surgery, Vol. 25, No. 3, 01.01.2014, p. 167-170.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phage therapy for Clostridium difficile infection

T2 - An alternative to antibiotics?

AU - Sangster, William

AU - Hegarty, John P.

AU - Stewart, David

PY - 2014/1/1

Y1 - 2014/1/1

N2 - As a consequence of their widespread use, a critical limitation in current antibiotic therapy is bacterial resistance. In the case of Clostridium difficile infection (CDI), current antibiotic regimens may not necessarily suffer due to drug resistance, though they have become increasingly ineffective due to the dysbiosis they induce, resulting in notoriously high recurrence rates. As a result, interest in alternative treatment modalities has recently surfaced. Amongst these emerging treatments, newer investigations are being invested in the older concept of bacteriophage therapy. This approach, first identified in the early 19th century, offers a more microbe-specific treatment option that can, theoretically, pointedly target C. difficile while sparing the other bacterial organisms of the human gut. The aim of this article is to explain the intellection behind bacteriophage therapy for the treatment of bacterial infections in humans, to review the historical research on bacteriophage therapy, and to introduce the reader to recent investigations into bacteriophage therapy for the treatment of CDI.

AB - As a consequence of their widespread use, a critical limitation in current antibiotic therapy is bacterial resistance. In the case of Clostridium difficile infection (CDI), current antibiotic regimens may not necessarily suffer due to drug resistance, though they have become increasingly ineffective due to the dysbiosis they induce, resulting in notoriously high recurrence rates. As a result, interest in alternative treatment modalities has recently surfaced. Amongst these emerging treatments, newer investigations are being invested in the older concept of bacteriophage therapy. This approach, first identified in the early 19th century, offers a more microbe-specific treatment option that can, theoretically, pointedly target C. difficile while sparing the other bacterial organisms of the human gut. The aim of this article is to explain the intellection behind bacteriophage therapy for the treatment of bacterial infections in humans, to review the historical research on bacteriophage therapy, and to introduce the reader to recent investigations into bacteriophage therapy for the treatment of CDI.

UR - http://www.scopus.com/inward/record.url?scp=84926206109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926206109&partnerID=8YFLogxK

U2 - 10.1053/j.scrs.2014.05.014

DO - 10.1053/j.scrs.2014.05.014

M3 - Article

AN - SCOPUS:84926206109

VL - 25

SP - 167

EP - 170

JO - Seminars in Colon and Rectal Surgery

JF - Seminars in Colon and Rectal Surgery

SN - 1043-1489

IS - 3

ER -